Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 11/20 | 0.63 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.46 |
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7040409 | 0.83 | CACNA1B (0.71) | CACNA1BDPP7KMT2A | |
| SCHEMBL7038930 | 0.78 | CACNA1B (1.00) | CACNA1BDPP7 | |
| SCHEMBL2866427 | 0.78 | CACNA1B (1.00) | CACNA1BDPP7 | |
| SCHEMBL2866423 | 0.78 | CACNA1B (1.00) | CACNA1BDPP7 | |
| SCHEMBL7045451 | 0.77 | CACNA1B (0.73) | CACNA1BDPP7PRMT5KMT2A | |
| Hydrochloric Acid SCHEMBL7038897 | 0.77 | CACNA1B (0.98) | CACNA1BDPP7 | |
| SCHEMBL7780744 | 0.77 | CACNA1B (0.43) | CACNA1BACACB | |
| SCHEMBL7040140 | 0.76 | CACNA1B (0.79) | CACNA1BDPP7PRMT5 | |
| SCHEMBL7045048 | 0.76 | CACNA1B (0.79) | CACNA1BDPP7PRMT5KMT2A | |
| SCHEMBL7038870 | 0.76 | CACNA1B (0.79) | CACNA1BDPP7PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009814-A1 | Pharmaceutical composition containing gabapentin or pregabalin and N-type calcium channel antagonist | AJINOMOTO CO., INC. (JP) | 2005-01-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009814-A1 | Pharmaceutical composition containing gabapentin or pregabalin and N-type calcium channel antagonist | CACNA1B, CACNA1G, CACNA1C | CACNA1B 1/4885DPP7 1216/4885ACACB 1155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.